1-3 of 3
Don W. Milligan
Close
Sort by
Journal Articles

The Combination of Fludarabine and Cyclophosphamide Has a Beneficial Effect on the Incidence of Hemolytic Anemia in Chronic Lymphocytic Leukemia. Results from the UK LRF CLL4 Trial.

Claire E. Dearden, MD, Rachel L. Wade, MSc, Monica Else, MSc, Sue M. Richards, DPhil, Don W. Milligan, MD, Terry J. Hamblin, MD, Daniel Catovsky, DSc
Journal: Blood
Blood (2007) 110 (11): 2044.
https://doi.org/10.1182/blood.V110.11.2044.2044
Published: 2007
Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD
Journal: Blood
Blood (2007) 110 (11): 752.
https://doi.org/10.1182/blood.V110.11.752.752
Published: 2007
Journal Articles

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

Clinical Trials & Observations
José A. Pérez-Simón, Panagiotis D. Kottaridis, Rodrigo Martino, Charles Craddock, Dolores Caballero, Raj Chopra, Javier Garcı́a-Conde, Don W. Milligan, Stephen Schey, Alvaro Urbano-Ispizua, Anne Parker, Angel Leon, Kwee Yong, Ana Sureda, Ann Hunter, Jordi Sierra, Anthony H. Goldstone, David C. Linch, Jesus F. San Miguel, Stephen Mackinnon
Journal: Blood
Blood (2002) 100 (9): 3121–3127.
https://doi.org/10.1182/blood-2002-03-0701
Published: 2002